Cannabis Sativa Inc (OTCMKTS: CBDS) is a really exciting Company in the booming cannabis space with a long history of spectacular moves rising to $18 a share n 2014 and $9 twice in 2017 and 2018.
Cannabis is booming; according to a recent report from Arcview Market Research and its research partner BDS Analytics, over the next 10 years, the legal cannabis industry will see much progress around the globe and spending on legal cannabis worldwide is expected to hit $57 billion by 2027. The adult-use (recreational) market will cover 67% of the spending; medical marijuana will take up the remaining 33%. The largest group of cannabis buyers will be in North America, going from $9.2 billion in 2017 to $47.3 billion a decade later. Of course much of this hinges on how laws progress
Cannabis Sativa Inc (OTCMKTS: CBDS) is engaged in the licensing of cannabis related intellectual property, marketing and branding for cannabis based products and services, operation of cannabis related technology services, and ancillary business activities. CBDS licenses the “hi” and “White Rabbit” brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, owns patent pending and trade secret formulas and processes, offers the hi benefits discount pharmacy card, and operates subsidiaries including: PrestoDoctor, Wild Earth Naturals and iBudtender. In addition, CBDS seeks strategic partners for acquisition of operating companies, intellectual property and other assets which fit within the CBDS corporate vision.
The Company owns a number of important patents including Patent PP27,475 for a Cannabis Plant named Ecuadorian Sativa and deemed “CTA”.Equadorian Sativa has been shown in laboratory testing by Steephill Labs to have a Limonene level that is extraordinarily high at a level of 4.53, 10 to 20 times the usual range. This sets Equadorian Sativa apart from other varieties in its odor, the effects on mood and its medical qualities. They also own Patent number 10105343 titled “Cannabis based compositions and methods of treating hypertension” on October 23, 2018. The invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage.
Last year CBDS acquired PrestoCorp an online telemedicine platform providing access to knowledgeable physicians for a safe and confidential way to get a medical marijuana recommendation using secure video conferencing technology.
Appointments through PrestoDoctor’s website are generally completed in 10-15 minutes, and can be scheduled and completed in the same day. This convenience eliminates the need for patients to travel to an in-person appointment or wait in line at a clinic. More than 40,000 users have registered to consult with PrestoDoctor’s 15+ licensed physicians across the United States. PrestoDoctor currently offers services in California and Nevada, and is actively targeting expansion into multiple additional states in the coming months.
CBDS subsidiary Wild Earth Naturals was conceived by formulators with more than 20 years of proprietary product development, well proven formulations and R&D in the Natural Health Products business. Wild Earth Naturals’ goal is to formulate, develop, and manufacture efficacious natural and organic products containing hemp. We will strive to alleviate any misconceptions people may have created about hemp, which is included prominently in our product line as a legal ingredient.
To Find out the inside Scoop on CBDS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
The Company has developed a number of products including Wild Earth Naturals CBD water which is formulated using what has been described as a “revolutionary” nano process that delivers ion-sized nutrients (the size that can move through cell membranes) encased with water molecules. The CBD source is pure and natural, and is provided exclusively by the 2015 CBD Concentrate award-winning Swiss company, Isodiol S.A. It is free of THC and therefore non-psychoactive. The high alkaline (9.5ph) half liter bottles contain one efficacious dose of cannabidiol as well as a balance of naturally occurring minerals – Potassium, Magnesium, Calcium, and electrolytes and is enhanced with d-Ribose, Methylcobalamin (methyl B12) and Coenzyme Q 10 (CoQ10)
Several years ago the Company said it has taken delivery of its initial order of 10,800 bottles of Wild Earth Naturals CBD water at the Company’s Mesquite, Nevada facility. The Wild Earth Naturals CBD Water is available now for sale on the Wild Earth Naturals website.
Last year CBDS acquired Ibudtender, the first truly smart cannabis web app tailored as a virtual budtender for patients, as well as a B2B & B2 app for dispensaries and cannabis businesses. Ibudtender’s preferential user and medical data makes it simple for patients, dispensaries, and consumers to locate cannabis, hemp and ancillary products while mitigating concerns regarding safety and effectiveness.
Last month CBDS announced Debby Goldsberry, a member of the Cannabis Sativa Board of Directors, tops the High Times list of their first ever ‘Women in Weed” themed issue. Women owners, executives and innovators were listed for their contributions, influence and accomplishments in cannabis. Debby Goldsberry was lauded as an advocate and owner operator of Magnolia Oakland Dispensary.
On October 15 CBDS announced the United States Patent Office will issue to CBDS the US Patent number 10105343 titled “Cannabis based compositions and methods of treating hypertension” on October 23, 2018. The invention relates to a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery comprising a pharmaceutically acceptable base and an effective amount of at least one cannabinoid or endocannabinoid containing extract of a cloned hybrid of the plant Cannabis sativa, subspecies sativa and Cannabis sativa, subspecies indica of the CTSX-ISS lineage.
CEO Mike Gravel said “We are excited to see the patent finally get issued. Cannabis Sativa made a bold deal acquiring this pending IP in the merger acquisition of Kush in 2014, which included Kubby Patent and Licenses. This lozenge patent is the second patent to be granted resulting from that agreement, following the December 2016 issuing of our patented marijuana strain, Ecuadorian Sativa. This coconut oil based lozenge is unique because of its rapid onset and long term effects, and is based on our patented strain of cannabis, Ecuadorian Sativa”, stated President David Tobias.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $102 million market valuation CBDS has $122k in the treasury, $30k in crypto, manageable debt and small but growing revenues reporting $301,064 for the 6 months ended June, 30 1018 up from $3k for the same period last year. CBDS is an exciting story in small caps; the Company behind the “hi” and “White Rabbit” brands has a number of subsidiaries making big moves. CBDS also has star power; the CEO Mike Gravel used to be a Senator and the Company’s director Debby Goldsberry recently topped the High Times list of their first ever ‘Women in Weed” themed issue CBDS has a long history of big moves rising to $18 a share n 2014 and $9 twice in 2017 and 2018. We will be updating on CBDS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CBDS.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in CBDS either long or short and we have not been compensated for this article.